Stock ISKJ HUMAN STEM CELLS INSTITUTE
Add to a list
To use this feature you must be a member
Log inSign up

News Human Stem Cells Institute

Equities

ISKJ

RU000A0JNAB6

End-of-day quote Moscow Micex - RTS
Other stock markets
 06:00:00 2022-07-07 pm EDT 		5-day change 1st Jan Change
59.54 RUB +1.43% Intraday chart for Human Stem Cells Institute -.--% -.--%
Apr. 26 Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Artgen Biotech PJSC Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Artgen Biotech PJSC Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Public Joint-Stock Company "Human Stem Cells Institute" Reports Earnings Results for the Full Year Ended December 31, 2022
CI
GENETICO PJSC has completed an IPO in the amount of RUB 178.8 million.
CI
GENETICO PJSC has filed an IPO.
CI
Public Joint-Stock Company "Human Stem Cells Institute" Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received RUB 611.63608 million in funding from PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy
CI
Public Joint-Stock Company "Human Stem Cells Institute" Reports Earnings Results for the Full Year Ended December 31, 2021
CI
International Medical Center of Biomaterials Processing and Cryostorage Public Joint-stock company acquired 6.93% stake in Public Joint-Stock Company "Human Stem Cells Institute".
CI
GENETICO LLC announced that it expects to receive RUB 228.948921 million in funding from Public Joint-Stock Company "Human Stem Cells Institute"
CI
Public Joint-Stock Company Human Stem Cells Institute Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it expects to receive funding from PJSC International Medical Center Processings and Kriokhraneniya of Biomaterialy
CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received RUB 400 million in funding from Limited Liability Company "IceGen 2"
CI
Public Joint-Stock Company Human Stem Cells Institute Reports Earnings Results for the Full Year Ended December 31, 2020
CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it has received funding from Limited Liability Company "IceGen 2"
CI
Public Joint-Stock Company "Human Stem Cells Institute" and Artur Isaev acquired 17.79% interest in GENETICO LLC from RVC Biopharmaceutical Investments, Limited liability Company, managed by RVC, Investment Arm.
CI
Public Joint-Stock Company "Human Stem Cells Institute" announced that it expects to receive funding from Limited Liability Company "IceGen 2"
CI
An unknown buyer acquired 15% stake in Human Stem Cells Institute PJSC from Mezhdunarodnogo Meditsinskogo Centra Obrabotki i Kriokhraneniya Biomaterialy.
CI
Human Stem Cells Institute PAO Announces Dividend
CI
Artur Isayev acquired 16.68% stake in Human Stem Cells Institute PJSC.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ISKJ Stock
  4. News Human Stem Cells Institute